Literature DB >> 25821874

Community-wide measures of wellness in a remote First Nations community experiencing opioid dependence: evaluating outpatient buprenorphine-naloxone substitution therapy in the context of a First Nations healing program.

Dinah Kanate, David Folk, Sharon Cirone, Janet Gordon, Mike Kirlew, Terri Veale, Natalie Bocking, Sara Rea, Len Kelly.   

Abstract

OBJECTIVE: To document the development of unique opioid-dependence treatment in remote communities that combines First Nations healing strategies and substitution therapy with buprenorphine-naloxone.
DESIGN: Quantitative measurements of community wellness and response to community-based opioid-dependence treatment.
SETTING: Remote First Nations community in northwestern Ontario. PARTICIPANTS: A total of 140 self-referred opioid-dependent community members. INTERVENTION: Community-developed program of First Nations healing, addiction treatment, and substitution therapy. MAIN OUTCOME MEASURES: Community-wide measures of wellness: number of criminal charges, addiction-related medical evacuations, child protection agency cases, school attendance, and attendance at community events.
RESULTS: The age-adjusted adult rate of opioid-dependence treatment was 41%. One year after the development of the in-community healing and substitution therapy program for opioid dependence, police criminal charges had fallen by 61.1%, child protection cases had fallen by 58.3%, school attendance had increased by 33.3%, and seasonal influenza immunizations had dramatically gone up by 350.0%. Attendance at community events is now robust, and sales at the local general store have gone up almost 20%.
CONCLUSION: Community-wide wellness measures have undergone dramatic public health changes since the development of a First Nations healing program involving opioid substitution therapy with buprenorphine-naloxone. Funding for such programs is ad hoc and temporary, and this threatens the survival of the described program and other such programs developing in this region, which has been strongly affected by an opioid-dependence epidemic.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25821874      PMCID: PMC4325865     

Source DB:  PubMed          Journal:  Can Fam Physician        ISSN: 0008-350X            Impact factor:   3.275


  6 in total

1.  A case series of buprenorphine/naloxone treatment in a primary care practice.

Authors:  Benjamin Doolittle; William Becker
Journal:  Subst Abus       Date:  2011-10       Impact factor: 3.716

2.  Prescribing of opioid analgesics and related mortality before and after the introduction of long-acting oxycodone.

Authors:  Irfan A Dhalla; Muhammad M Mamdani; Marco L A Sivilotti; Alex Kopp; Omar Qureshi; David N Juurlink
Journal:  CMAJ       Date:  2009-12-07       Impact factor: 8.262

3.  Treating opioid addiction with buprenorphine-naloxone in community-based primary care settings.

Authors:  Ira L Mintzer; Mark Eisenberg; Maria Terra; Casey MacVane; David U Himmelstein; Steffie Woolhandler
Journal:  Ann Fam Med       Date:  2007 Mar-Apr       Impact factor: 5.166

4.  Home buprenorphine/naloxone induction in primary care.

Authors:  Joshua D Lee; Ellie Grossman; Danae DiRocco; Marc N Gourevitch
Journal:  J Gen Intern Med       Date:  2008-12-17       Impact factor: 5.128

5.  Home- versus office-based buprenorphine inductions for opioid-dependent patients.

Authors:  Nancy L Sohler; Xuan Li; Hillary V Kunins; Galit Sacajiu; Angela Giovanniello; Susan Whitley; Chinazo O Cunningham
Journal:  J Subst Abuse Treat       Date:  2009-10-03

6.  Office-based treatment of opiate addiction with a sublingual-tablet formulation of buprenorphine and naloxone.

Authors:  Paul J Fudala; T Peter Bridge; Susan Herbert; William O Williford; C Nora Chiang; Karen Jones; Joseph Collins; Dennis Raisch; Paul Casadonte; R Jeffrey Goldsmith; Walter Ling; Usha Malkerneker; Laura McNicholas; John Renner; Susan Stine; Donald Tusel
Journal:  N Engl J Med       Date:  2003-09-04       Impact factor: 91.245

  6 in total
  19 in total

1.  Opioid use disorder and type 2 diabetes mellitus: Effect of participation in buprenorphine-naloxone substitution programs on glycemic control.

Authors:  Devon Tilbrook; Jeffrey Jacob; Pierre Parsons; Craig Edwards; Kassandra Loewen; Len Kelly
Journal:  Can Fam Physician       Date:  2017-07       Impact factor: 3.275

2.  Hypothesizing That Neuropharmacological and Neuroimaging Studies of Glutaminergic-Dopaminergic Optimization Complex (KB220Z) Are Associated With "Dopamine Homeostasis" in Reward Deficiency Syndrome (RDS).

Authors:  Kenneth Blum; Marcelo Febo; Lyle Fried; Mona Li; Kristina Dushaj; Eric R Braverman; Thomas McLaughlin; Bruce Steinberg; Rajendra D Badgaiyan
Journal:  Subst Use Misuse       Date:  2016-12-29       Impact factor: 2.164

3.  Narcotic tapering in pregnancy using long-acting morphine: an 18-month prospective cohort study in northwestern Ontario.

Authors:  Roisin Dooley; Joe Dooley; Irwin Antone; John Guilfoyle; Lianne Gerber-Finn; Kara Kakekagumick; Helen Cromarty; Wilma Hopman; Jill Muileboom; Nicole Brunton; Len Kelly
Journal:  Can Fam Physician       Date:  2015-02       Impact factor: 3.275

4.  First Nations hepatitis C virus infections: Six-year retrospective study of on-reserve rates of newly reported infections in northwestern Ontario.

Authors:  Janet Gordon; Natalie Bocking; Kathy Pouteau; Terri Farrell; Gareth Ryan; Len Kelly
Journal:  Can Fam Physician       Date:  2017-11       Impact factor: 3.275

Review 5.  Primary care management of opioid use disorders: Abstinence, methadone, or buprenorphine-naloxone?

Authors:  Anita Srivastava; Meldon Kahan; Maya Nader
Journal:  Can Fam Physician       Date:  2017-03       Impact factor: 3.275

6.  Future directions for medication assisted treatment for opioid use disorder with American Indian/Alaska Natives.

Authors:  Kamilla L Venner; Dennis M Donovan; Aimee N C Campbell; Dennis C Wendt; Traci Rieckmann; Sandra M Radin; Sandra L Momper; Carmen L Rosa
Journal:  Addict Behav       Date:  2018-05-23       Impact factor: 3.913

7.  Evaluation of 6 remote First Nations community-based buprenorphine programs in northwestern Ontario: Retrospective study.

Authors:  Solomon Mamakwa; Meldon Kahan; Dinah Kanate; Mike Kirlew; David Folk; Sharon Cirone; Sara Rea; Pierre Parsons; Craig Edwards; Janet Gordon; Fiona Main; Len Kelly
Journal:  Can Fam Physician       Date:  2017-02       Impact factor: 3.275

8.  A collaborative approach to hepatitis C testing in two First Nations communities of northwest Ontario.

Authors:  David Smookler; Anne Beck; Brenda Head; Leroy Quoquat; Cheyanne Albany; Terri Farrell; Janet Gordon; Nancy Thurston; Lucy You; Camelia Capraru; Mike McKay; John Kim; Jordan J Feld; Hemant Shah
Journal:  Can Liver J       Date:  2022-08-16

Review 9. 

Authors:  Anita Srivastava; Meldon Kahan; Maya Nader
Journal:  Can Fam Physician       Date:  2017-03       Impact factor: 3.275

10.  Quantifying opioid use disorder Cascade of Care outcomes in an American Indian tribal nation in Minnesota.

Authors:  Thaius Boyd; Jordan Stipek; Alex Kraft; Judge Muskrat; Kevin A Hallgren; Clinton Alexander; Brenna Greenfield
Journal:  Drug Alcohol Depend       Date:  2021-03-18       Impact factor: 4.492

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.